前收市價 | 16.47 |
開市 | 16.47 |
買盤 | 11.00 |
賣出價 | 19.00 |
拍板 | 270.00 |
到期日 | 2025-06-20 |
今日波幅 | 16.47 - 16.47 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 18 |
Leqembi, which works by removing a toxic protein called beta amyloid from the brain, is the first Alzheimer's treatment proven to alter the course of the fatal, brain-wasting disease. Eisai has also collaborated with a major Chinese medical insurance firm to plan partial coverage of the drug cost, the companies said without naming the insurer. China approved the treatment in January after a standard approval from the U.S. Food and Drug Administration last July.
Is Eli Lilly stock a buy as it looks to enter the obstructive sleep apnea treatment market? Is LLY stock a buy right now?
The FDA grants priority review to Ionis' (IONS) filing seeking approval for olezarsen to treat adults with familial chylomicronemia syndrome. A final decision is expected in December 2024.